Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory ...
On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...
The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...
(Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on ...
Rimowa is one of LVMH's fastest growing brands thanks to its ultra-popular sleek aluminum luggage. The cheapest carry-on ...
The global pharmaceutical drug delivery market is set to grow from USD 1,949.4 billion in 2024 to USD 2,546.0 billion by 2029 ...
1,5 Full efficacy and safety data from the trial will be presented in the first half of 2025. Boehringer Ingelheim will submit a new drug application for nerandomilast for the treatment of IPF to the ...
UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its ...
In a leap forward for chronic kidney disease (CKD) screening, Healthy.io, the global leader in transforming the smartphone ...
Boehringer Ingelheim, Eli Lilly, Menarini Pharmaceuticals, and Novo Nordisk and was deputy chair of Diabetes Research Group-2 until December 2023 (no conflict of interest directly related to this work ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback